Extract
Noninvasive ventilation (NIV) is an evidence-based treatment for patients developing acute respiratory failure due to an exacerbation of COPD [1]. NIV has proven to reduce work of breathing, enhance gas exchange, reduce the length of hospital stay and to reduce the risk of endotracheal intubation and mortality, regardless of whether NIV is applied within the intensive care unit (ICU) or on the pulmonary ward [1–3]. NIV is therefore recommended to serve as a first-line intervention in patients with acute hypercapnic respiratory failure due to an exacerbation of their COPD.
Abstract
The study of Hartley designed an easy-to-use score to predict mortality in noninvasively ventilated COPD patients. More information about NIV is gained, but the exact measures on how to improve NIV in clinical practice remains uncertain. https://bit.ly/3tFfg8F
Footnotes
Conflict of interest: J. Elshof reports grants from Vivisol BV and Fisher and Paykel Ltd, outside the submitted work.
Conflict of interest: M.L. Duiverman reports grants and personal fees for lectures from Philips BV and Vivisol BV, grants and personal fees for lectures and advisory board work from RESMED Ltd, grants from Fisher and Paykel Ltd, outside the submitted work.
Conflict of interest: P.J. Wijkstra reports grants and personal fees from Philips and RESMED, grants from Goedegebuure and Vital Air, personal fees from Bresotec and Synapse, outside the submitted work.
- Received February 3, 2021.
- Accepted February 3, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org